 |
Thomas G. Pretlow II, M.D.Professor, EmeritusMailing Address: fax: (216) 368-0494 email: Thomas.Pretlow@Case.edu |
Biography
Dr. Tom Pretlow received his M.D. from the University of Rochester Medical School in 1965. His internship
and fellowship training in Medicine and Pathology was at University Hospitals, Madison, Wisconsin. He
also conducted a research associateship at the National Cancer Institute, NIH. His professional
experience includes an Assistant Professorship at Rutgers Medical School (1969-71), followed by
numerous appointments at the University of Alabama (1971-1983) where he became Professor of Pathology
(1974) and Professor of Biochemistry. In 1983, he moved to Case Western Reserve University, where he
is currently a Professor of Pathology, Oncology, Environmental Health Sciences, and Urology.
Research
Our laboratory is focused on the pathogenesis and the estimation of prognosis for two kinds of cancer in
humans and, to a lesser degree, in experimental animals. These are prostate and colon cancers. We want
to understand those characteristics of cancer that are involved in initiation and particularly in
promotion and/or progression. The approaches used in our laboratory include immunological,
biochemical, histochemical, immunohistochemical, cytogenetic, and molecular genetic techniques. Recently,
the study of factors that control the growth of prostate cancer cells from patients' blood has been useful
in our prostate and colon cancer studies.
Publications
Cheng L, Song S-Y, Pretlow TG, Abdul-Karim FW, Kung H-J, Dawson DV, Park W-S, Moon Y-W, Tsai M-L, Linehan
WM, Emmert-Buck MR, Liotta LA, Zhuang Z (1998). Evidence of independent origin of multiple tumors from
patients with prostate cancer. J Natl Cancer Inst 90, 233-237.
Dawson DM, Lawrence EG, MacLennan GT, Kung H-J, Robinson D, Resnick MI, Kursh ED, Pretlow TP, Pretlow TG (1998). Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 90, 519-523.
Qui Y, Robinson D, Pretlow TG, Kung H-J (1998). Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6- induced neuroendocrine differentiatioin of prostate cancer cells. Proc Natl Acad Sci USA 95, 3544-3649.
Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS (1999). Androgen receptor up- regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 140, 2372-2381.
Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamoeki E, Schraml P, Moch WNH, Elkahlhoun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi O (1999). Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91, 1758-1764.
Pretlow TG, Pretlow TP (2000). Models of prostate cancer. Resnick MI, Thompson IM (eds.) Advanced Therapy of Prostatic Disease. Hamilton, pp. 138-153, Ontario, Canada: B. C. Decker, Inc.
Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, Murphy JR, Markowitz SD, Jamison JM, Summers JL, Hamlin CR, MacLennan GT, Resnick MI, Pretlow TP, Connell CF (2000). Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res 60, 4033-4036.
Korkmaz KS , Korkmaz CG, Ragnhildstveit E, Pretlow TG, Saatcioglu F (2000). An efficient procedure for cloning hormone-responsive genes from a specific tissue. DNA Cell Biol 19, 499-506.